Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

New patient treatment in the clinical phase 1 study

The fourth patient has been treated on February 22, 2018 in the Phase 1 study conducted by SpectraCure for the treatment of patients with relapse of prostate cancer. The treatment was performed at Princess Margaret Cancer Centre in Toronto, Canada, and passed without complications and the patient is doing well. The treatment method, called Photodynamic Treatment (PDT), means that the patient is given a light-activated drug that accumulates in the tumor. When the cancer tissue is illuminated using SpectraCures instruments, the medicine is activated and the tumour is eliminated. The

Montebello to distribute Biohit products in Norway

Biohit Oyj Press release, February 23rd, 2018 at 10:00 a.m. local time (EET) Biohit Oyj and Montebello Diagnostics AS have signed an agreement for the distribution of Biohit diagnostic products in Norway. The contract has been signed for three years with a continuation option. Managing Director Mika Søderberg, Montebello Diagnostics AS: “The Biohit product range will significantly strengthen our portfolio of gastrointestinal tract diagnostics. GastroPanel® innovation is welcome to the Norwegian health care to promote safe and cost-effective diagnosis and screening of dyspepsia as well

Atria Plc: Managers' transactions

Atria Oyj - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Kiinteistö Oy ItikanmäkiPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Flink ReijoPosition: Member of the Supervisory Board (2):Person Discharging Managerial Responsibilities In IssuerName: Ritola AhtiPosition: Member of the Supervisory Board (3):Person Discharging Managerial Responsibilities In IssuerName: Sairanen RistoPosition: Member of the Supervisory

SelfieSign is the future

Effortless. Practical. Lazy. In our perpetual search for more convenience, digitalisation had yielded a world of e-this and e-that. Undoubtedly such inventions do make our lives easier. Take mobile signing, for instance. Long gone is the circus of printing, mailing by post, scribbling illegible autographs, scanning and then perhaps emailing, in contract management. Mobile signing – eSigning that works on your phone – has removed wasted time and hassle. We already use biometrics, voice recognition and Facebook authentication for online transaction, but it’s not always necessary. Such user

Epiroc Capital Markets Day on May 30, 2018

Stockholm, Sweden, February 23, 2018: Epiroc AB, the company that the Atlas Copco Group plans to dividend out to shareholders this year, will host its first annual Capital Markets Day on May 30, 2018, in Örebro, Sweden.The purpose of the Capital Markets Day is to present Epiroc and its strategy to investors, analysts and financial media. The event will also provide an update on the process of publicly listing Epiroc on the Nasdaq Stockholm stock exchange, planned for mid-2018, provided that Atlas Copco shareholders approve the proposal at the Annual General Meeting on April 24, 2018.

Year-End Report 2017

2017 – An intense year during which we established the base for an aggressive market expansion!Q4 2017 · Net sales for the period amounted to SEK 0.8 (0.3) million. · Earnings for the period amounted to SEK -19.9 (-11.7) million, which corresponds to earnings per share of SEK -0.86 (-1.27). During the quarter a provision of SEK 2.3 million related to replacements of previous deliveries was made for some of the first commercial projects. · Cash and cash equivalents as at December 31 amounted to SEK 38.5 million. · During the quarter, ChromoGenics invoiced and completed

Year-end report 2017 1 January - 31 December

Climeon AB (publ) releases fourth quarter and full year 2017 reportFinancial development, October - December • Order intake amounted to SEK 12.6 million (0.0)  • Net sales amounted to SEK 11.1 million (2.5) • Operating profit/loss amounted to SEK ‐20.2 million (‐13.3) • Earnings per share amounted to SEK ‐0.48 (‐0.38) • Cash amounted to SEK 204.0 million (51.3) • New share issues provided a total of SEK 224.0 million net • Cash flow from operating activities amounted to SEK ‐22.1 million (‐8.9) Important events, October ‐ December • An order of SEK 12.6 million

YEAR-END REPORT 1 OCTOBER – 31 DECEMBER 2017

Fourth quarter 2017, compared to 2016, Group » Gross order intake amounted to SEK 885,088 (626,306), an increase of 41,3% » Order backlog amounted to SEK 893,014 (325,434), an increase of 174,4% » 38% growth in orders for Episealer® knee implants during the quarter with 36 (26) approved orders » Group net sales amounted to SEK 884,088 (1,007,759) » Loss before tax amounted to SEK –15,547,283 (–18,454,211) » Loss per share (weighted average) amounted to SEK –0.51 (–0.97) Significant events during the fourth quarter » Episealer® 24 months’ clinical study results

Episurf Medical presents strategy update, new external financing and long-term operating targets

Episurf Medical (NASDAQ: EPIS B) today presents a strategy update, a new financing agreement and long-term operating targets. The company is close to launching an important and comprehensive clinical multicenter study in the US and Europe and the company has entered into early collaborative discussions regarding the US market.Episurf Medical addresses significant medical needs not currently met by the orthopaedic industry, and the company’s vision is to bring more people back to fully living life. The business implementation of this vision is to provide orthopaedic surgeons with clinically

Episurf Medical AB (publ) secures external financing of up to SEK 70 million and will issue free warrants to its existing shareholders

Episurf Medical AB (publ) ("Episurf") has signed an agreement relating to a financing of up to SEK 70 million. The capital will be used for execution of the company’s growth strategy. The transaction is carried out through the issuance of convertible notes (the “Notes”) with warrants attached (the “Warrants”) in several tranches spread over 36 months (each a ”Tranche”). Episurf will receive SEK 7 million through the first Tranche. Existing shareholders will receive free warrants to protect them against dilution. The financing is conditioned upon the shareholders' meeting resolving on a new

Year-End Report 2017, Heliospectra AB ( publ)

(GOTHENBURG, Sweden / SAN FRANCISCO, CA, February 23, 2018) – Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, are today presenting its Year-End Report for 2017.Financial Report October-December: · Net sales amounted to SEK 16,489 thousand (6,864)· Operating profit/loss was KSEK -7,478 (-12,468), involving a negative operating margin (neg)· Profit/loss after tax was KSEK -7,470 (-15,354) or SEK -0,21 (-0,44)  per share· Operating cash flow was KSEK -3,556 (-2,009).

EQT strengthens position as a leading investor and owner – closes eighth Equity fund at EUR 10.75 billion

· EQT VIII holds first and final close at EUR 10.75 billion hard cap (USD 13.2 billion) · Strong support for EQT’s responsible investment and ownership approach – growth, transformation and “future-proofing” of high-quality companies · Official launch of EQT VIII in September 2017 – less than six months in fundraising EQT today announces that the eighth fund within the Equity investment strategy, EQT VIII (or the “fund”), held a first and final close at its hard cap of EUR 10.75 billion. The fund officially launched in September 2017. Investor demand from both existing and new

Conditions fulfilled in Icelandic geothermal deal

· Order now binding as pre-conditions are met  · Baseload Capital provides financing to Varmaorka The key pre-conditions of Climeon's deal with Icelandic Heat power operator Varmaorka (owned by CP Energy) have been met. Delivery of the first seven modules will now begin. At the same time Baseload Capital Sweden AB has agreed to fund the first phase of the deal, enabling Climeon to focus on production and deliveryPer the agreement, first reported in August 2017, Varmaorka will buy 100 modules from Climeon, an order with a total value of more than 30 MEUR. The first phase of the order

Alimak Group: Fourth Quarter and Full Year 2017

Solid finish of a strong 2017 · Increased revenues for the Group in the quarter · EBITA margin adj. in Q4 at 13.8% · Significant contribution by the acquired companies to Group order intake and salesFourth quarter ·  Order intake increased by 111% to MSEK 1,096 (519) with organic decrease of 6% ·  Revenue increased by 76% to MSEK 1,050 (598) with organic growth of 4% ·  EBITA adj. increased to MSEK 145 (105), margin 13.8% (17.6) ·  EBITA increased to MSEK 127 (75), margin 12.1% (12.6) ·  EBIT increased to MSEK 113 (75), margin 10.8% (12.6) ·  Net profit

Invitation to Clas Ohlson Capital Markets Day 3 May 2018

Clas Ohlson invites analysts, investors and media to a Capital Markets Day in Stockholm to be held on 3 May 2018.The aim of the Capital Markets Day is to present Clas Ohlson’s updated strategy for future growth. The President and CEO Lotta Lyrå and other Clas Ohlson representatives will conduct presentations during the afternoon, providing further insights to Clas Ohlson’s strategy and business. Location: GT30, Grev Turegatan 30, Stockholm, Sweden Date and time: 3 May 2018 12:45-13:00     Registration13:00-17:00     Presentations and Q&A17:00-18:00     Refreshments

Swedbank’s Annual Report 2017 published

Swedbank’s Annual and Sustainability Report for 2017 has been published at www.swedbank.com/ir together with the bank’s Risk Management and Capital Adequacy Report 2017.Swedbank’s sustainability work is a central part of the bank’s operations and the sustainability report is thus an integral part of the Annual Report. For further information:Gabriel Francke Rodau, Head of Group Communications, phone: + 46 70 144 89 66Gregori Karamouzis, Head of Investor Relations, phone: + 46 72 740 63 38Fredrik Nilzén, Head of Group Sustainability, phone: +46 76 773 19 26 Swedbank AB (publ) is

Additional US patent to be granted regarding IntelliGel

The United States Patent and Trademark Office (USPTO) has communicated its intention to grant a new US patent in the portfolio licensed to Redwood Pharma from Broda International LLC. A new US patent will, when granted, provide enhanced patent protection in the United States for the so-called IntelliGel platform, which is used, inter alia, in the development of Redwood Pharmas RP101 product."We are very pleased that the protection of RP101, our drug for the treatment of chronic dry eye in women, and for other ophthalmological products, will be strengthened. As soon as the patent is granted,

Strengthened financial position and solid earnings and profit growth

Fourth quarter: October-December 2017  · Net sales amounted to SEK 283.7 (237.7) million, an increase of 19.3 percent or SEK 46 million. The increase was entirely organic.   · Operating profit (EBIT) was SEK 26.3 (15.4) million, an increase of 70.3 percent. The result in the quarter includes costs for the IPO of SEK 11.2 million. Operating profit adjusted for items affecting comparability was SEK 37.4 (32.9) million, corresponding to an adjusted operating margin of 13.2 (13.8) percent.   · Net profit after tax was SEK 20.0 (3.7) million.   · Earnings per share, before and

Nomination Committee’s proposed Board composition for JM AB’s 2018 Annual General Meeting

The Nomination Committee of JM AB has decided to propose the following to the 2018 Annual General Meeting regarding the composition of the Board of Directors.Number of Board Members: seven ordinary members, no deputies.  The Nomination Committee proposes the re-election of Fredrik Persson as Chairperson of the Board (elected 2017). The Nomination Committee proposes the re-election of Members Kaj-Gustaf Bergh (elected 2013), Olav Line (elected 2017), Eva Nygren (elected 2013), Kia Orback Pettersson (elected 2010), Åsa Söderström Jerring (elected 2007) and Thomas Thuresson (elected 2016).

MyFC Holding (publ) financial report January – December 2017

Significant events October – December· Patents granted in Sweden and Canada · MyFC initiates development project to halve weight of LAMINA Range Extender for electric vehicles · MyFC declares JAQ Hybrid ready for delivery, expects orders from Telling to be delayed · MyFC initiates feasibility study with leading Chinese smartphone manufacturer Significant events after the end of the quarter · Skandia Fonder and Handelsbanken Fonder invest in myFC through a targeted issue · myFC introduces fuel cells as a feasible alternative to batteries in energy density and production

Nynas reports fourth quarter and full year results 2017

Nynas increased its sales volumes by 5 per cent in the fourth quarter and by 7 per cent for the full year, compared to 2016. The operating result for the quarter (EBITDA) amounted to SEK 396 million (44) and for the full year to SEK 1,218 million (1,009).“The overall business environment was good in 2017 with sales revenues and margins for naphthenic specialty oils well above the level seen in the previous year. Our bitumen sales also had a strong development in key markets,” commented Gert Wendroth, President and CEO of Nynas AB. FOURTH QUARTER SUMMARY · Total product sales volumes

MSAB: Comment on sales of shares

"With a 2017 behind us where both sales and results noted a new record level, I now look forward to continuing to develop and grow MSAB. I speak for both Örjan Gatu and me when I say that the shares we divested in February should not be misunderstood as a diminished belief in the company and its future. The both of us still have significant shareholdings in the company and, above all, I have an unremitting commitment to MSAB's very exciting growth trip. I look forward with confidence to continuing to lead, develop and grow MSAB. " Stockholm, February 2018 Joel BollöChief Executive

Sweco to coordinate the planning and approval process of the new DC connection A-Nord power line in Germany

Sweco has been commissioned by Amprion GmbH to advice in the planning of the new DC connection A-Nord power cable that will transfer renewable energy from the North of Lower Saxony to North Rhine-Westphalia in Germany. Sweco will support the approval and planning processes as main coordinator.“The new power cable will support Germany in its shift to renewable energy as it will transfer wind power to North Rhine-Westphalia. We are looking forward to working together with Amprion GmbH on this important large-scale project”, says Ina Brandes, President of Sweco Central Europe. DC Connection

Read original

Aker ASA: Jan Arve Haugan appointed as Chief Executive Officer of Aker Energy

Jan Arve Haugan has been appointed as Chief Executive Officer of the newly established oil company Aker Energy, effective 1 March 2018. Mr. Haugan is currently the President & CEO of Kværner ASA ("Kvaerner")."We are pleased that Jan Arve Haugan has accepted the management responsibility of Aker Energy. Jan Arve has extensive experience from international top management and the oil and gas industry. He has also been responsible for implementing one of Norway's largest industrial projects abroad," said President & CEO of Aker, Øyvind Eriksen. Aker Energy AS is a 50-50 joint venture between

There are no items matching the current filter
There are no more items matching the current filter
Back to top